A Randomized Pilot Study Comparing infection Rates in Myeloablative Allogeneic Stem Cell Transplant Patients Receiving a Non-Neutropenic Diet or a Neutropenic Diet  by Lassiter, M. & Adler, A.
S360 Poster Session IIprocedures, incidences of underutilization and over-allocation
from a scheduling perspective, along with review of overtime
employment of staff, generated further root cause assessment
of several concerning patterns of poor utilization along with
poorly managed spikes in volume which can generate patient
safety risk and employee burn-out. Based on the analysis, a cen-
tralized scheduling process for apheresis was developed and im-
plemented using the existing GE/IDX platform. New guidelines
for apheresis scheduling based on clinical criteria as well as new
rules for scheduling were activated. Restructuring of cell pro-
cessing technical staff work schedules and procedure scheduling
were implemented based on a new assessment of demand and
greater management of procedure scheduling during each pro-
cessing day. Outcomes include significantly greater actual
throughput, improved efficiency of the scheduling process itself,
nearly eliminated overtime, higher staff satisfaction among cell
processing technicians, and reduction of risk-generating volume
spikes.577
OUTPATIENT PHARMACY ESTIMATE OF CHARGE FINANCIAL COUNSEL-
LING
Cruz, E.D., Bramwell, D.P., Shaw, S., Ifokwe, M., Lang, M.,
Lewis, M.S. UT MD Anderson Cancer Center, Houston, TX
Planning for the stem cell transplant (SCT) patient’s discharge is
complex requiring a multidisciplinary team (MDT) approach. Chal-
lenges identified by the MDT include costly prescription co-pays
and limited pharmacy coverage which is overwhelming and frustrat-
ing to patient and MDT.
This challenge led to the creation of a MDT task force. Based on
several meeting discussions and MDT feedback, an outpatient phar-
macy estimate of charge (EOC) process was developed and an EOC
form was designed to address pharmacy co-pays/deductible, high-
dollar prescriptions, annual lifetime maximum and potential dis-
charge medication list, with a goal to counsel all patients prior to
SCT admission.
In October 2009, the Related Coordinator started the new pro-
cess by scheduling the patient’s pharmacy EOC counseling at the
time of pre-admission work-up. The Patient Access Specialist
(PAS) verifies prescription benefits from the health insurance
and reviews coverage with the patient, who signs the EOC form
after counseling. The Patient Access Coordinator addresses ques-
tions related to the medications. The PAS faxes the signed EOC
to the case manager who reviews the EOC with the patient when
planning for discharge. Patients are counseled at the bedside
when appointment is missed. Texas residents who are unable to
financially meet the co-pays/deductible or have limited benefits
are provided with a Supplemental Financial Assistance applica-
tion. The Pharmacy Reimbursement Specialist counsels all Medi-
care, Indigent and Self-pay patients for Pharmacy Assistance
Program.
As a result, patient’s verbalized marked decrease in their anxiety
and increased knowledge on their benefits empowering them to
make informed decisions regarding their discharge prescriptions.
Identification of limited pharmacy coverage prior to SCT admission
enables the MDT timely intervention to address the patient’s di-
lemma. Pharmacy counseling coupled with the EOC form as
a tool enhanced the quality of patient care, increased patient satisfac-
tion and MDT greater job fulfillment.TRANSPLANT NURSING-RESEARCH
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A RANDOMIZED PILOT STUDY COMPARING INFECTION RATES IN MYE-
LOABLATIVE ALLOGENEIC STEM CELL TRANSPLANT PATIENTS RECEIV-
ING A NON-NEUTROPENIC DIET OR A NEUTROPENIC DIET
Lassiter, M., Adler, A. Duke University Health System, Durham, NC
Purpose: The primary objective of this study is to compare the in-
cidence of grade 3 or 4 bacteremia as defined by the NCI CommonTerminology Criteria for Adverse Events (CTCAE) v4.0.in patients
undergoing myeloablative allogeneic stem cell transplant when re-
ceiving a neutropenic diet or a non-neutropenic diet. Secondary ob-
jective is to assess the nutritional status of patients undergoing
myeloablative allogeneic stem cell transplant in those receiving
a neutropenic diet as compared to those receiving a non-neutropenic
diet using the Scored Patient-Generated Subjective Global Assess-
ment (PG-SGA).
Materials andMethods:To date, a convenience sample of 18 mye-
loablative allogeneic hemotopoietic stem cell transplant patients
have been randomized to receive either a neutropenic or non-
neutropenic diet during their period of neutropenia. Several nutri-
tional standard indicators, CBC, and PG-SGAwere assessed weekly.
Blood cultures were obtained per unit standard.
Results: When comparing maximum change in prealbumin, trans-
ferrin, and days of TPN, only borderline statistical difference is de-
tected. Wilcoxon Rank-sums p 5 0.056. The median number of
TPN days for the controls is 18 and for the experimental group
it’s 13, Wilcoxon Rank-sums p5 0.5; therefore, it is not statistically
different. 25% of the controls have a grade 3 blood stream infection
compared to 40% of the experimental, the chi-square test for com-
paring these proportions is 0.50; therefore, these proportions are
not statistically significantly different. No grade 4 blood stream
infections were noted during neutropenia.
Conclusions: This small sample set does not show any significant
difference in grade 3 or 4 infections between the arms of the study.
Days of TPN and overall nutritional status does not appear to be sig-
nificant as well.
Limitations: Small sample size, inconsistent patient recording of
food diaries.
Future directions: Continue enrollment in this study to increase
statistical power of results.579
PALONOSETRON VERSUS ONDANSETRON IN CHEMOTHERAPY INDUCED
NAUSEA AND VOMITTING
Vieira, S., Monroe, D. Trustees of London Clinic, London, United
Kingdom
Introduction: Palonosetron is a longer acting -5 hydroxytrypta-
mine-3 (5-HT3) antagonist, used in preventing chemotherapy in-
duced nausea and vomiting (CINV). It is licensed initially for the
oncology patient group. It is given as an injection and acts over
a five days period.
Method: In our haematology setting we have conducted a small
comparison study to compare the efficiency of Palonosetron and
Ondansetron for haematology patients for preventing CINV. Stage
1 data was collected prospectively for Palonosetron over a year pe-
riod. Second stage data was collected for efficiency of Ondansetron
retrospectively, simply because Ondansetron is the main anti-
sickness drug used in our centre. Patients who were in the Ondan-
setron group were selected randomly without any information
given to ward nurses. The information was collected day 1- day
11 from the day chemotherapy started. There were 24 patients in
each group.
The data was compared in three different categories: complaints of
nausea (severity), vomiting (how many episodes over 24 hour) and
the requirement of additional anti-sickness.
The patients in both groups received similar chemotherapy regi-
mens. Patient demographic data and chemotherapy regimen are
shown Table I.
Result: Due to limited word count of this abstract, the outcome is
evaluated on two sections instead of three: severity of nausea and fre-
quency of vomiting.
According to our study, patients who received Palonosetron suf-
fered less from mild nausea. In this group a maximum of seven pa-
tients reported mild nausea where as 12 patients were reported
similar episodes in the Ondansetron group.
However, in the evaluation of vomiting, there was a trend in the
Palonosetron group. Those patients receiving Palonosetron had
their sickness/ vomiting peak on day 4. Palonosetron was given day
5, where the vomiting subsidised again. However 46% of patients
